Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The results were shown in multiple posts on X. A clinical trial to prove the safety and efficacy of Elon Musk's brain implant is ongoing, with 12 people currently using the devices.
The all-cash deal is expected to be finalized in April 2026. With this divestment of its ambulatory labs, Tennessee-based Community Health Systems said it will be better able to focus on its core patient care business.
Artera, a company that utilizes AI for patient communications, made the announcement while revealing it has achieved $100 million in annual revenue. Its products use AI for follow-ups after patient care, in addition to supporting clinical decisions.
Authorities allege the pharmacy chain gave patients more insulin than prescribed and then billed Medicare and Medicaid for the full amounts. This allegedly occurred for more than a decade.
The two companies have been unable to assuage antitrust concerns raised by the Department of Justice. A magistrate will attempt to hammer out acceptable terms for the home healthcare merger at a conference scheduled for August.
The company said part of its network has been encrypted. However, it told the Securities and Exchange Commission it is still able to deliver dialysis care to patients.
UnitedHealth Group said it is seeking repayment of “interest-free” advances distributed to providers struggling during the shutdown of claims processing caused by the ransomware attack on Change Healthcare.
Monoclonal antibody therapies will be the first drugs permitted to take advantage of alternatives, including advanced lab simulations and artificial intelligence. A pilot framework to phase out the decades-long requirement for animal testing will be rolled out in the coming year, the FDA said.
The Department of Health and Human Services is looking to replace lab animals with AI models. Even more bullish on AI is the new boss at the Centers for Medicare and Medicaid Services.
GenAI initiatives are complex and—in some cases—costly. “As such, the main rationale for pursuing them needs to be business growth, not workforce reductions.”
The authors of the survey report note that AI tools mentioned by respondents run the gamut from automated appointment reminders to dynamic “care gap” messaging.